U.S. Markets open in 2 hrs 44 mins

Galapagos NV (GLPG)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
60.540.00 (0.00%)
At close: 4:00PM EDT
62.12 +1.58 (2.61%)
Pre-Market: 05:03AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close60.54
Open60.96
Bid62.13 x 900
Ask61.97 x 900
Day's Range60.44 - 61.24
52 Week Range56.79 - 195.74
Volume148,835
Avg. Volume314,019
Market Cap4.002B
Beta (5Y Monthly)0.34
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation
    GlobeNewswire

    Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation

    Biologic effect of salt inducible kinase (SIK) mechanism in first patient studies supports further progression of Toledo portfolioSIK2/3 inhibitor GLPG3970 generally safe and well-toleratedStudy in psoriasis patients shows improvement in PASI score at Week 6Study in ulcerative colitis (UC) patients shows signs of biologically important effects; does not translate to signal on Mayo score at Week 6 No signal observed in rheumatoid arthritis (RA) study at Week 6 Mechelen, Belgium; 14 July 2021; 22.

  • Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study
    GlobeNewswire

    Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study

    Generally safe and well toleratedPositive efficacy signal in psoriasis patients at Week 440% of patients showed improvement of at least 50% in PASI response (PASI 50) with high dose of GLPG3667 at Week 4Data support initiation of Phase 2b dose finding study in psoriasis Mechelen, Belgium; 14 July 2021; 22.01 CET; regulated information - Galapagos NV (Euronext & Nasdaq: GLPG) reports positive topline results with tyrosine kinase 2 (TYK2) inhibitor GLPG3667 in a Phase 1b study in psoriasis patient

  • Galapagos announces new data supporting rapid symptom improvement and sustained steroid-free remission with filgotinib in patients with Ulcerative Colitis
    GlobeNewswire

    Galapagos announces new data supporting rapid symptom improvement and sustained steroid-free remission with filgotinib in patients with Ulcerative Colitis

    New post-hoc analyses of data from SELECTION Phase 3 program presented at European Crohn’s and Colitis Organisation (ECCO) virtual congress Mechelen, Belgium; 10 July 2021, 11.10 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced new post-hoc analyses from the Phase 3 SELECTION program, supporting the activity and tolerability of filgotinib, a once-daily, oral JAK1 preferential inhibitor, under investigation for the treatment of patients with moderately to severely active ulcerative col